Table 2.
Biological activity of 1–8.
| IC 50 (nM)a | |||||
|---|---|---|---|---|---|
| compound | UACC257 | LOX-IMVI | M14 | MCF7 | NCI-H460 |
| melanoma | breast | lung | |||
| precandidaspongiolide A/B (1/2) | 14.2 ± 0.2 | 6.9 ± 1.0 | 17.9 ± 4.3 | 8.3 ± 0.5 | 12.3 ± 1.0 |
| candidaspongiolide A/B (3/4) | 1.6 ± 0.5 | 2.0 ± | 7.5 ± 1.5 | 2.0 ± | 3.4 ± 0.2 |
| tedanolide (5) | 5.9 ± 0.1 | 2.5 ± 0.4 | 8.6 ± 2.4 | 3.6 ± 0.3 | 7.0 ± 3.9 |
| 28-acetyl-precandidaspongiolide A (6) | 103.8 ± 3.4 | 34.2 ± 9.4 | 261.0 ± 63.9 | 98.6 ± 12.5 | 96.8 ± 15.7 |
| 11R-dihydro-precandidaspongiolide A (7) | 16.7 ± 2.2 | 10.3 ± 0.3 | 25.1 ± 0.5 | 12.4 ± 1.2 | 43.7 ± 16.6 |
| 11S-dihydro-precandidaspongiolide A (8) | 423.1 ± 57.4 | 275.3 ± 20.0 | 505.6 ± 94.0 | 368.8 ± 19.1 | 433.4 ± 17.5 |
a
IC50 cytotoxicity values were determined as the drug concentration that reduced cell growth to 50% of the untreated control.